Compare CPAC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | URGN |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.9M | 1.1B |
| IPO Year | 2012 | 2017 |
| Metric | CPAC | URGN |
|---|---|---|
| Price | $10.38 | $23.00 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.15 | ★ $28.50 |
| AVG Volume (30 Days) | 203.3K | ★ 773.4K |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.31% | N/A |
| EPS Growth | ★ 20.27 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $601,081,883.00 | $96,516,000.00 |
| Revenue This Year | $9.96 | $27.96 |
| Revenue Next Year | $1.70 | $123.20 |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | 6.18 | ★ 8.00 |
| 52 Week Low | $5.10 | $3.42 |
| 52 Week High | $11.30 | $30.00 |
| Indicator | CPAC | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 73.92 | 48.27 |
| Support Level | $10.27 | $22.60 |
| Resistance Level | $10.69 | $24.14 |
| Average True Range (ATR) | 0.55 | 1.17 |
| MACD | 0.24 | -0.08 |
| Stochastic Oscillator | 80.36 | 46.53 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.